p53 and Neu (c-erbB-2) Overexpression in Relation to Risk Factors for Breast Cancer

  • Karin van der Kooy
  • Matti A. Rookus
  • Hans L. Peterse
  • Flora E. van Leeuwen
Conference paper


Different types of breast cancer, with and without protein overexpression of neu (c-erbB-2) or p53, were studied to determine whether there was an association with known risk factors for breast cancer. Neu and p53 protein expressions were evaluated by immunohistochemistry in primary breast tumor samples from a series of patients aged 20–54 years, who participated in a case-control study. Neu overexpression was shown in 117 out of 597 tumors (19.6%) and p53 overexpression in 142 out of 528 tumors (26.9%). Diagnosis at a young age (≤35 years) was found to be associated with p53 and neu overexpression. Age at first full-term pregnancy (≥29 years) was more strongly related to neu[+] than to neu[−] tumors. Other risk factors were not significantly associated for breast tumors categorized according to neu or p53 protein expression.


Breast Cancer Polytomous Logistic Regression Invasive Breast Cancer Case Scattered Staining Risk Factor Association 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kelsey JL. (1993) Breast cancer epidemiology: Summary and future directions. Epidemiol Rev 15:256–63.PubMedGoogle Scholar
  2. 2.
    Van de Vijver MJ (1993) Molecular genetic changes in human breast cancer. Adv Cancer Res 61:25–56.PubMedCrossRefGoogle Scholar
  3. 3.
    Van de Vijver, et al. (1988) Neu-protein overexpression in breast cancer. N Engl J Med 319:1239–45.PubMedCrossRefGoogle Scholar
  4. 4.
    Cattoretti G, et al. (1993) Antigen unmasking on formalin-fixed paraffin embedded tissue sections. J Path 171:83–98.PubMedCrossRefGoogle Scholar
  5. 5.
    Fisher CJ, et al. (1994) Problems with p53 immunohistochemical staining. Brit J Cancer 69:26–31.PubMedCrossRefGoogle Scholar
  6. 6.
    Hall PA, Lane DP (1994) p53 in tumour pathology. J Path 172:1–4.PubMedCrossRefGoogle Scholar
  7. 7.
    Pietenpol JA, Vogelstein B (1993) No room at the p53 inn. Nature 365:17–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Jacquemier J, et al. (1994) P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies. Brit J Cancer 69:846–52PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 1996

Authors and Affiliations

  • Karin van der Kooy
  • Matti A. Rookus
  • Hans L. Peterse
  • Flora E. van Leeuwen

There are no affiliations available

Personalised recommendations